Shilpa Medicare zooms after its arm completes Human Clinical studies of High concentration Biosimilar Adalimumab
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Shilpa Medicare is currently trading at Rs. 399.85, up by 11.65 points or 3.00% from its previous closing of Rs. 388.20 on the BSE.
The scrip opened at Rs. 395.00 and has touched a high and low of Rs. 407.50 and Rs. 392.30 respectively. So far 26724 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 657.95 on 14-Oct-2021 and a 52 week low of Rs. 380.35 on 07-Mar-2022.
Last one week high and low of the scrip stood at Rs. 407.50 and Rs. 382.60 respectively. The current market cap of the company is Rs. 3490.30 crore.
The promoters holding in the company stood at 50.01%, while Institutions and Non-Institutions held 16.40% and 33.59% respectively.
Shilpa Medicare via its wholly owned subsidiary, Shilpa Biologicals (SBPL), has successfully completed the phase 3 Human Clinical studies of its first biosimilar, the 100mg/ml High Concentration (HC) Adalimumab biosimilar and has submitted the dossier to the CDSCO for review and grant of marketing/manufacturing license - a first in India.
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets - diseases where India has the largest patient populations.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
